Dr. Andrea B. Apolo, MD from the National Cancer Institute discusses the next steps and moving Checkpoint Inhibitors from metastatic advanced setting to earlier disease states in urothelial cancers. ASCO GU 2016 in San Francisco
Advertisement
[the_ad id="32629"]
Moving Checkpoint Inhibitors from metastatic advanced setting to earlier disease states in urothelial cancers
By Editor